返回
J
Jinho Shin
College of Medicine
36H指数
564论文数
6.0K被引数
收录论文 150
发表时间
Response to Letter to the Editor: “Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial”回复致编辑函:“厄贝沙坦和S-氨氯地平低剂量联合疗法在高血压患者中的疗效与安全性:一项随机、双盲、多中心、治疗确证性、III期临床试验”
Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized; Double-Blind; Multicenter; Phase III Study缬沙坦/吲达帕胺联合疗法与缬沙坦单药疗法在未充分响应缬沙坦30 mg治疗的原发性高血压患者中的疗效与安全性比较(FINEDUO研究):一项随机、双盲、多中心、III期研究
Corrigendum to “Multicenter, Randomized, Double-Blind, Parallel, Phase 2 Clinical Trial to Compare and Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension” (Clin Ther. 2025 Oct 28. [Epub ahead of print])勘误:“多中心、随机、双盲、平行、2期临床试验,比较并评估SPC1001和单药治疗在原发性高血压患者中的疗效和安全性”(Clin Ther. 2025年10月28日。[电子版优先出版])
A Phase III Randomized, Double-Blind, Active-Controlled, Multicenter Study on the Efficacy and Safety of Ezetimibe/Atorvastatin/Amlodipine Combination in Patients With Comorbid Primary Hypercholesterolemia and Essential Hypertension一项关于依折麦布/阿托伐他汀/氨氯地平联合疗法在伴发原发性高胆固醇血症和原发性高血压患者中有效性与安全性的III期随机、双盲、活性药物对照、多中心研究

